Antibacterial Haemostatic Gels Market Size

Antibacterial Haemostatic Gels Market size was valued at USD 1.49 billion in 2024 and is set to exceed USD 3.3 billion by 2037, expanding at over 6.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of antibacterial haemostatic gels is evaluated at USD 1.57 billion. The increase in surgical techniques across the world will primarily drive the antibacterial haemostatic gels market In many of these conditions, the use of surgical and anesthesia care is required, making up a functional, adaptable, and resilient health system. The demand for surgical services in these regions will increase significantly from now until 2030 due to the significant increase in the incidence of cancer, road traffic accidents, and cardiovascular and metabolic diseases in LMICs. The practice of performing manual operations, or surgery, has a rich history dating back to antiquity.

Another reason that will propel the market of antibacterial haemostatic gels by the end of 2036 is the increasing prevalence of wound infection globally. Globally, between 9.1 and 26.1 million people are affected by FUs each year. A recent report raises the population's estimate to 40 to 60 million, citing various factors, including the DFU definition, the surveillance approach, and wound care access. The rise in bacterial resistance to antibiotics is likely to cause an increase in the burden of chronic wound infections worldwide. More than 6.5 million chronic wounds with evidence of bacterial infection are identified annually in the United States of America alone. In addition, several studies have identified the polymicrobial environment as a risk factor for the development of resistance to several antibiotics, including the third-generation cephalosporins used in the Mbarara Regional Referral Hospital for chronic wound infections.